Skip to main content
PLOS One logoLink to PLOS One
. 2023 Mar 2;18(3):e0281434. doi: 10.1371/journal.pone.0281434

Imaging breast malignancies with the Twente Photoacoustic Mammoscope 2

S M Schoustra 1,2, B De Santi 1, T J P M op ’t Root 3, C A H Klazen 4, M van der Schaaf 4, J Veltman 1,5, W Steenbergen 2, S Manohar 1,*
Editor: Jeeun Kang6
PMCID: PMC9980787  PMID: 36862628

Abstract

Clinical measurements on breast cancer patients were performed with a three-dimensional tomographic photoacoustic prototype imager (PAM 2). Patients with a suspicious lesion, visiting the center for breast care of a local hospital, were included in the study. The acquired photoacoustic images were compared to conventional clinical images. Of 30 scanned patients, 19 were diagnosed with one or more malignancies, of which a subset of four patients was selected for detailed analysis. Reconstructed images were processed to enhance image quality and the visibility of blood vessels. Processed photoacoustic images were compared to contrast-enhanced magnetic resonance images where available, which aided in localizing the expected tumoral region. In two cases, spotty high-intensity photoacoustic signals could be seen in the tumoral region, attributable to the tumor. One of these cases also displayed a relatively high image entropy at the tumor site, likely related to the chaotic vascular networks associated with malignancies. For the other two cases, it was not possible to identify features indicative of malignancy, because of limitations in the illumination scheme and difficulties in locating the region of interest in the photoacoustic image.

Introduction

Photoacoustic imaging is being thoroughly researched for its potential role in, among many other areas, breast cancer management [1, 2]. Breast cancer is the cancer type in females with the highest number of newly diagnosed cases each year [3]. The current clinical imaging methods for detection, diagnosis and evaluation of breast cancer have advantages, but also drawbacks. Photoacoustics is a noninvasive functional imaging method that does not use ionizing radiation, a contrast agent nor apply breast compression. The breast is illuminated with short pulses of light. Selective absorption of the light takes place in the tissue, and thermal expansion in turn generates ultrasound waves that can be detected outside the body and reconstructed into an image. When choosing a wavelength of light which is strongly absorbed by hemoglobin, we obtain a map of the vasculature, which is of interest given the relationship between vascularization and cancer progression [4]. The method could potentially have a role in the area of breast cancer management, if it proves to have an added value over current methods.

Three-dimensional photoacoustic imaging of breast cancer has been reported earlier [510]. Toi et al. scanned 22 patients with malignant breast tumors with their PAM-03 system, employing a hemispherical detector array with 512 elements [7]. The breast was illuminated with two wavelengths: 755 and 795 nm. PA images were analyzed as well as fused MR-PA images. In the latter, MR an PA images were registered after MR images were deformed to match sizes and orientations in PA images using common landmarks in both modalities. From manual counting of trunks and branches of blood vessels after elimination of subcutaneous vessels, it was concluded that often, there were more PA signals considered to be of blood vessels in the affected breast than in the contralateral breast. Differences between PA appearance of ductal carcinoma in situ cases (DCIS) and invasive breast cancers were studied. Significantly more centripetal blood vessel structures were found in invasive breast cancers compared to the DCIS cases. Many invasive breast cancer cases showed vessel disruption or rapid narrowing at the boundary of the tumor. In one case, changes in intratumoral blood vessels were observed after chemotherapy. Hypoxic spotty signals could be seen in the tumor, not present before therapy. After upgrading the system to PAI-04 [8], with higher frequency detectors and the co-acquisition of ultrasonic images among other advances, another breast tumor was imaged. The three-dimensional US image aided in identifying the tumor position. Fine, tumor-related blood vessels could be visualized as well as scattered hypoxic points, hypothesized to be attributable to intratumoral bleeding.

Lin et al. detected all nine tumors (of which six were invasive carcinomas) in seven patients with their single-breath-hold photoacoustic tomography (SBH-PACT) system [9]. The entire breast was illuminated with 1064 nm and scanned within ~15 seconds. Eight out of nine tumors were detected at the expected location by observing higher blood vessel densities. A vessel density map of the breast was calculated and a threshold was set to distinguish high vessel densities from normal vessel densities. The one tumor that was not detected by looking at abnormal vessel densities, was identified by investigation of the compliance of the breast tissue (photoacoustic elastography). A difference in compliance between the tumoral region and surrounding normal tissue indicated the ninth tumor. The same system was used to evaluate response to neoadjuvant chemotherapy (NAC) [10]. Three breast cancer patients receiving NAC treatment were scanned before, during and after treatment. Again, vessel density maps were calculated to distinguish the tumor region from healthy tissue. Moreover, entropy and anisotropy were evaluated. Binarized anisotropy-weighted entropy maps were employed to acquire cancer masks, which in turn were used to calculate and evaluate tumor sizes.

Heijblom et al. imaged 33 malignancies with the first generation Twente Photoacoustic Mammoscope (PAM) system, employing a planar configuration where the breast was mildly compressed in a craniocaudal direction [5, 6]. In 32 out of 33 cases, the malignancy could be identified through PA imaging. Photoacoustic lesion appearance was studied and three main types were observed: ‘mass’, ‘non-mass’ and ‘ring’. By comparing PA images not only to MR images but also to vascular stained histopathology (for some cases), PA intensities were attributed to the presence of vascularity. Continuing research on photoacoustic mammography, the second generation Twente Photoacoustic Mammoscope (PAM 2) was developed, where some of the limitations of PAM 1 were overcome. PAM 1 had a limited field of view (90 × 80 mm2 detector surface area), made use of breast compression and the flat 2D detector array complicated 3D visualization of lesions. In PAM 2 the breast is pendant in water without any compression, with illumination and ultrasound detection from around the breast. Illumination is performed with 10 beams (as opposed to one large beam in PAM 1), where one beam is directed at the ventral side of the breast, and nine smaller beams directed at the region of the breast close to the chest wall. Further, illumination can be provided at 2 wavelengths 755 and 1064 nm (as opposed to single-wavelength illumination at 1064 nm in PAM 1). The ultrasound detectors are arranged as 12 arcs with 32 elements each around the breast; the arc-shapes follow the pendant breast contour. Over the course of 1.5 years, we performed a clinical study with our prototype tomographic PAM 2 system for breast imaging [11, 12]. Thirty patients were measured, with benign as well as malignant abnormalities (diagnosed by conventional imaging modalities and/or histopathologic examination). The aim of this study was to investigate or find possible markers indicative of malignancy. In this paper, we show in depth results of four case studies, all breast cancer patients with one or more malignant breast lesion. Reconstructed images are processed and compared to contrast-enhanced MR images if available. Per case, a tailormade image analysis was done and observations of the photoacoustic appearance of the tumoral region are presented.

Materials and methods

Study design and clinical setting

Photoacoustic measurements were performed on patients visiting the center for breast care of the Medisch Spectrum Twente hospital (Oldenzaal, The Netherlands). Patients with a lesion suspicious for malignancy, classified as BI-RADS 4 or 5 through clinical investigation and conventional diagnostic imaging, were asked to participate in our study. Also, patients who came to the hospital with a suspicious lesion which was classified as BI-RADS 2 or 3 after clinical investigation and conventional diagnostic imaging were asked to participate. All subjects were adults and fully competent to give informed consent. Exclusion criteria were: a breast biopsy in the six months prior to this study; bloody discharge, ulcers or wounds on the breast; a history of surgery (including cosmetic surgery) or radiation therapy on the breast; chemotherapy at the time of this study. A cup size of D or larger was an exclusion criterion. Approval for the study protocol and procedures was obtained from an institutional review board (METC Twente, Medisch Spectrum Twente, Enschede, The Netherlands) and the study was registered in the Netherlands National Trial Register (NL6010). Written informed consent was obtained from all participating patients.

Upon arrival at the hospital, each patient had a physical examination and anamnesis by a nurse practitioner. Then, conventional images were obtained (x-ray and/or US). For patients referred through the screening program, the x-ray screening images were examined and in some case additional x-ray imaging was performed. Craniocaudal (CC) and mediolateral-oblique (MLO) tomosynthesis x-ray images of both breasts were obtained with a Hologic Dimensions 3D Mammography system (Hologic, Inc., Marlborough, Massachusetts). US imaging was done with a Philips EPIQ 5G system (Koninklijke Philips N.V., Amsterdam, The Netherlands), with the L12-5 50 mm linear array transducer and/or the L18-5 broadband linear array transducer, depending on tissue and lesion characteristics and radiologist’s experience. If somewhere in this process, a patient met all inclusion criteria and was willing to participate, PAM 2 scans of both breasts were made. This was always done after or in between regular imaging procedures, and always before a US-guided core needle biopsy (if applicable). A subset of patients was scheduled for MR imaging, when additional imaging information was needed for diagnosis and/or treatment planning. For this, a Philips Ingenia 3.0T system (Koninklijke Philips N.V., Amsterdam, The Netherlands) was used with a dStream breast 16ch coil. High-resolution, anatomic T2-weighted images and dynamic T1-weighted images were obtained before and after administration of gadolinium contrast medium. All conventional images were interpreted by a breast radiologist and biopsy specimens were examined by a pathologist. Radiologists’ and histopathologists’ reports were made available to the researchers. Final diagnoses were either based on US (in the case of cysts) or histopathological examination.

PAM 2 system

The PAM 2 system was first described in Ref. [11] and is shown in Fig 1. The tomographic system images one breast at a time, inside an imaging tank filled with water while the subject lies prone on a bed. The pendant breast is illuminated by a dual-head laser (755 and 1064 nm) by multiple beams: one directed at the nipple (50% of the energy) and nine directed at the sides (50% of the energy is spread over these nine fibers bundles) of the breast. US signals are detected with 12 arc-shaped arrays, each containing 32 piezocomposite elements (Imasonic SAS, Voray-sur-l’Ognon, France) with a center frequency of 1 MHz. The imaging tank, including illumination bundles and detector arrays, rotates around the breast in steps. In this way, 45 projection angles (total covered angle of 60 deg) are acquired and in each position, signals of 35 pulses of each wavelength are averaged. Obtaining a scan of one breast following this protocol took approximately four minutes. The breast containing a lesion was scanned as well as the contralateral breast. Subjects were scanned with one breast freely pendant in the water inside the imaging tank. For reconstruction of images, a filtered backprojection algorithm was employed using averaged signals, as described in Ref. [11]. The algorithm was supplemented with an iterative scheme (five iterations), as described in Ref. [12]. Images were reconstructed with a homogeneous speed of sound (SOS) based on the coupling water temperature [13], which was measured during each scan. The resolution of all reconstructed volumes (voxel size) is 0.4 mm in each direction.

Fig 1. PAM 2 system in hospital setting with (A) the bed on which a woman lies prone, (B) a foot rest, and (C) the breast aperture with (D) a schematic of the shape and position of the imaging tank below the bed, (E) the power supply and cooling unit, (F) laser head (behind the panel), (G) DAQ unit, and (h) step stool.

Fig 1

Reproduced from Ref. [11] with permission of authors and publisher.

Image processing and interpretation

A subset of measurements was excluded from further analysis based on quality assessment. The absence of the visibility of a breast contour and/or nipple, as well as the presence of smears indicative of blurring due to motion artifacts were indications of unacceptable quality. Quite often, very few or even no discernable blood vessels were reconstructed in these images. Secondly, based on information available from the clinic, the visibility of the region(s) of interest (ROI), containing one or more malignancies, was investigated for each measurement. In cases where MR images were available, these were compared to PA images to identify landmarks and locate the expected lesion location. Measurements for which it was concluded that the ROI was not imaged properly with PAM 2 were excluded from further analysis.

From the remaining subset, four subjects with a malignant lesion were chosen for further analysis. Reconstructed scans of these subjects were processed mainly for two reasons: (i) improving the visualization of blood vessels; and (ii) assessing the ability of quantitative image biomarkers to distinguish tumoral tissue from healthy tissue in the images.

A processing pipeline was adopted for every selected subject All processing steps were done with MATLAB (R2021b, The MathWorks, Inc., Natick, Massachusetts). Fig 2 shows the results of all steps for one of the scanned patients (case 1). The 755 nm and 1064 nm reconstructed PA volumes were loaded and intensity values were scaled from 0 to 1 (Fig 2A and 2B). Median filtering with a moving kernel of 3 × 3 × 3 voxels was performed in order to reduce noise (Fig 2C and 2D). Frangi vesselness filtering [14] was applied in order to enhance the contrast of blood vessels in the images (Fig 2E and 2F). To further improve image contrast, adaptive intensity modulation was applied [15]. In this, the Frangi vesselness filtered images were modulated by dividing them by standard deviation maps. During this process, the image was split into 11 × 11 × 11 voxel patches. The intensity of the voxels was normalized to the standard deviation of the intensities within the patch. Hereby, portions of the image with low variability were enhanced in order to bring out structures that would otherwise not be visible in the image, while portions with high variability in intensity were attenuated. As a main result, this improved images in terms of homogeneity of the voxel intensities, mitigating the problem of non-homogeneous illumination. The final processed images were obtained by summing the modulated image with the median filtered images (Fig 2G and 2H).

Fig 2. Processing pipeline.

Fig 2

Coronal view maximum intensity projections of case 1 are shown, to illustrate the different processing steps. Top row shows images obtained by illuminating the left breast of the patient with 755 nm, bottom row shows the same breast illuminated with 1064 nm.

If available, MR images were studied and compared to PA images. PA images were transformed (rotation and axes flipping) to match the conventional image orientation system of MR images. Maximum intensity projections (MIPs) of tissue slabs with varying thicknesses (from 5 to 20 mm) were computed for PA as well as MR images, to make the image comparison easier. By scrolling through these slabs, similarities between vascular structures in MR and PA were sought, which was helpful in locating the tumoral region.

Next to the processing pipeline as described above, we also calculated entropy maps. They statistically describe the degree of randomness of the distribution of PA amplitudes in local regions of the image. Since angiogenesis induces the formation of chaotic vascular networks, one of the expected image features would be the presence of vessels showing abrupt changes in amplitude [10]. First, the local entropy was calculated. A cubical moving window of 4 × 4 × 4 mm was used to scan the whole volume and obtain a local entropy map. Due to rapid transitions between background tissue and blood vessels, also healthy structure can present high local entropy values. Therefore, the obtained entropy map was corrected using the response of a vesselness filter [14]. The local entropy map was then corrected with the vesselness filter response, to obtain the final entropy map. In this study, we report the entropy maps only for one case (case 3), which showed relatively good illumination in the region of the tumoral and nearby regions. For other cases, this was not the case, complicating interpretation of an entropy map.

Results

From March 2018 until November 2018, 33 patients were included in the study. See Table 1 for an overview. Of this group, three women were not measured: two subjects were unable to climb and/or lie prone on the imaging bed, and one subject could not be measured due to technical issues with the system. In general, both breasts were scanned. For two patients, one of the breasts was not scanned because of a history of surgery or amputation of one breast. Out of 30 measured patients, 19 were finally diagnosed with a malignant abnormality (M in Table 1). In this work, we focus on investigation of PAM 2 appearance of malignancies. Of these 19 patients, a selection of four was made to be thoroughly analyzed in this paper. The 15 patients with diagnoses of malignancies that were not included in this selection, were studied outside the scope of this work, where photoacoustic images of these patients were found to either: (i) be of such low quality that it was hard or even impossible to discern the boundary of the breast, the nipple, and/or vasculature; or (ii) contain smears or blurring, due to motion artifacts; or (iii) not have optimal positioning of the region of interest (ROI) containing the malignancy (as deduced from conventional imaging and/or clinical descriptions).

Table 1. Study overview.

First patient Last patient Included Measured Dx
B M
March 2018 November 2018 33 30 11 19

‘Dx’ = final diagnosis, ‘B’ = benign lesion, ‘M’ = malignant lesion.

S1 Table shows an overview of the characteristics of all 30 measured subjects. The average age of the 30 subjects was 53, of which the youngest was 30 and the oldest 79 years of age at the time of inclusion. Further, S1 Table shows the diagnosis of the suspect lesion, location and size, and the availability of MR images. Estimated lesion size was measured on MR images when available, otherwise it was estimated from x-ray and/or US images. When the lesion size was measured in three dimensions, the largest dimension is reported. In cases where satellite lesions were detected through MR, the reported size refers to the main lesion. Final diagnoses were either based on US (in the case of cysts) or histopathological examination, which was performed on excised (biopsied) tissue and/or specimens obtained from a lumpectomy or mastectomy. The latter is only mentioned for the four selected patients in Table 2, which summarizes characteristics of these four subjects.

Table 2. Characteristics of the four breast cancer patients and subjects, studied in detail.

Case Estimated size of lesion (mm) Diagnosis biopsy Treatment Histopathology after treatment
1 19 Invasive carcinoma NST grade 1 DD tubular carcinoma, multicentric Mastectomy Invasive carcinoma NST grade 1
2 39 Invasive carcinoma NST grade 3 Mastectomy Invasive carcinoma NST grade 3
3 33 Intraductal papillary carcinoma (uncertain) Mastectomy Mucinous carcinoma
4 25 Invasive carcinoma NST grade 3 NAC + lumpectomy Invasive carcinoma NST grade 2

‘NST’ = no specific type, ‘DD’ = differential diagnosis, ‘NAC’ = neoadjuvant chemotherapy.

Case studies

Case 1

Patient 1 (58 years old) was referred to the hospital through the national screening program. X-ray images showed dense structures, with most dense tissue in upper outer quadrants of both breasts. Centrally located in the upper part of the left breast, architectural distortion with a spiculated mass was observed, which was classified as suspicious (BI-RADS 5) (Fig 3A). US investigation (Fig 3B) revealed a suspect mass with a diameter of 12 mm, at 11 or 12 o’clock in the left breast (L1). A smaller lesion (4 mm) was located slightly more ventrally in the breast (L2), lateral to the other mass. Three 14G biopsies were taken from the largest mass. Histopathological examination of the specimens revealed an invasive carcinoma no special type (NST) or a tubular carcinoma (differential diagnosis), Bloom and Richardson grade 1. Additional MR investigation (Fig 3C) showed a total of five suspicious lesions (of which one was the pathology-proven carcinoma), located centrally and medially in the left breast. Based on this, a multifocal carcinoma in the left breast was suspected. Histopathological examination after mastectomy revealed two tumor foci, both invasive carcinomas NST of grade 1.

Fig 3. Case 1: Diagnostic images of a multifocal carcinoma in the left breast.

Fig 3

L and R indicate left and right, respectively. (A) Craniocaudal x-ray (CC-MMG), with the suspect mass indicated by L1. (B) Ultrasound (US) image, where the main lesion is indicated with blue and a satellite lesion with pink. (C) Perfusion maximum intensity projection magnetic resonance (MR) image. The initially detected mass is indicated by L1. The satellite lesion as detected by US is L2. Three more foci were found though MR investigation: L3, L4 and L5. All scale bars represent 20 mm.

Photoacoustic reconstructions were processed through the steps described in Section 2.3. Fig 4A and 4B show processed photoacoustic MIPs of slabs with a thickness of 20 mm in the coronal plane, close to the chest wall. It was attempted to show the same slab of tissue in Fig 4A and 4B as in Fig 4C, where we can identify one of the tumor foci (L1). Fig 4C shows a MIP of a slab of 20 mm of a post-contrast MR image. L1 points at one of the five tumor foci from Fig 3C. The vascular structure indicated with V2 in Fig 4 has a similar appearance in both modalities and can therefore serve as a landmark. V1 points at another vessel, identifiable in all 3 images. The photoacoustic images do not show anything remarkable at the expected tumor location. However, it is difficult to exactly pinpoint the expected location, given the lack of recognizable landmarks nor anatomical overlap between the two modalities.

Fig 4. Case 1: Local MIPs of slabs with a thickness of 20 mm, near the main lesion, close to the chest wall, in the coronal view.

Fig 4

Photoacoustic images at 755 nm (A) and 1064 nm (B), compared to a post-contrast dynamic T1 MR MIP image (C). All scale bars represent 20 mm.

Photoacoustic reconstructions at both wavelengths, in the coronal and transverse plane, are presented and compared to post-contrast dynamic T1 MR MIPs in the same two planes in S1 Fig.

Case 2

Patient 2 (79 years old) presented with a suspicious mass of 25 mm in the lower inner part of the right breast, located right under the skin. Local skin retraction was observed. X-ray imaging showed a mass at 6 o’clock, situated against the thoracic wall (Fig 5A). Part of the lesion was outside the field of view, making it difficult to assess lesion dimensions. The lesion presented on US as a lobed mass, surrounded by hyperechogenic tissue (Fig 5B). The estimated size was around 30 mm. Two 14G biopsies were taken from the BI-RADS 5 mass, which were indicative of a grade 3 invasive carcinoma NST upon histopathological investigation. The same mass was identified on MR images (Fig 5C) and was measured to be 36 × 25 × 35 mm. There was no ingrowth of the lesion into the pectoralis muscle. No other (new or satellite) lesions were found through MR investigation. The patient had a mastectomy of the right breast. Histopathological examination of the lesion in the removed breast confirmed the diagnosis of an invasive carcinoma NST grade 3.

Fig 5. Case 2: Diagnostic images of an invasive carcinoma in the right breast.

Fig 5

L and R indicate left and right, respectively. (A) Craniocaudal x-ray (CC-MMG). (B) Ultrasound (US) image, where the lesion is clearly visible (C) Perfusion maximum intensity projection magnetic resonance (MR) image. All scale bars represent 20 mm.

Photoacoustic images were processed via the method described in Section 2.3. Fig 6A and 6B show processed MIPs in the sagittal plane. The post-contrast dynamic T1 MR MIP in Fig 6C shows similar structures. V1 indicates a large blood vessel going towards the tumor, visible in all images and with a similar shape. V2 indicates a prominent vessel with a recognizable bulge. The tumor is well visible on the post-contrast MR of Fig 6C, in the dashed box in the inferior part of the breast. This part of the breast is shown enlarged in Fig 6E, where a projection of a slab with thickness 50 mm was made, containing the entire tumor. Window level and width values were adjusted to enhance contrast and visibility of the tumor and its surrounding vessels. A similar enlarged view of the same region of the PA MIP image at 1064 nm is shown in Fig 6D. The expected location of the tumor and thus the dashed box was deduced from structures V1 and V2. Arrowheads in Fig 6D point at spotty structures possibly attributable to the smaller tumor-related vessels or to higher intensity regions within the tumor, as seen in Fig 6E. The latter is more likely, since the small vessels seem to be positioned in line with V1, and the spotty signals appear above that.

Fig 6. Case 2.

Fig 6

Photoacoustic MIPs at 755 nm (A) and 1064 nm (B) in the sagittal plane. (C) Post-contrast dynamic T1 MR MIP in the sagittal plane. (D) Zoomed subsection of (B). (E) Zoomed subsection of the region marked in (C), where a MIP of a slab of tissue with thickness 50 mm is taken (containing the entire tumor); contrary to (C), where a projection of the entire breast is taken. All scale bars represent 20 mm.

Photoacoustic reconstructions at both wavelengths, in the two other planes (coronal and transverse), are presented as MIPs and compared to post-contrast dynamic T1 MR MIPs in the same two planes in S2 Fig.

Case 3

Patient 3 (78 years old) self-detected a palpable lump in the left breast and was referred to the specialized breast clinic for further investigation. The abnormality had a size of approximately 30 mm and was located behind the nipple-areolar complex. X-ray images showed a sharply delineated lesion with embedded calcifications at the location of the palpable abnormality (Fig 7A). Targeted ultrasound (US) examination showed a lobed, sharply delineated, mostly solid but also partly cystic lesion at 9 o’clock in the areola (Fig 7B). In the center of the lesion a duct was visible which was connected to the nipple. The calcifications were visible with US as well. The lesion measured 33 mm on US. Intravascular vascularization was visualized by means of color Doppler. Three 14G core needle biopsy (CNB) specimens were taken from the most solid part of the lesion as identified on the US images as suspicious (BI-RADS 4). X-ray and US showed confusing features, leading to a broad differential diagnosis, including invasive ductal carcinoma, papillary tumor, phyllodes tumor, complex fibroadenoma and fibrocystic changes. Histopathological investigation of the biopsy specimens was suggestive of an intraductal papillary carcinoma, although atypical (BI-RADS 6). Mucinous carcinoma was also considered, but not all parts of the specimen were in line with that diagnosis. The pathologist was not certain based on the biopsy specimens. The patient had a surgery two weeks later. Histopathological investigation of the resected tumor revealed the tumor to be a mucinous carcinoma.

Fig 7. Case 3: Diagnostic images of a mucinous carcinoma in the left breast.

Fig 7

L and R indicate left and right, respectively. (A) Craniocaudal x-ray (CC-MMG). (B) Ultrasound (US) image. All scale bars represent 20 mm.

Photoacoustic images were again processed as described in Section 2.3. Fig 8A and 8C show processed MIPs of both wavelengths, in the transverse and sagittal plane respectively. For this patient, MR images were not available. However, the tumor location is apparent from physical examination and x-ray images: directly behind the nipple and very superficial. This region is indicated with a dotted ellipse in all views in Fig 8. In the PA images in the top row (Fig 8A and 8C), we can see many small spots with a relatively high intensity behind the nipple. Entropy maps corrected with a vesselness filter in the same views are depicted in Fig 8B and 8D. It can be seen that the region behind the nipple shows a relatively high level of entropy, best visible in the transverse plane (Fig 8B).

Fig 8. Case 3: Photoacoustic maximum intensity projections (MIPs) and entropy maps in two planes, at two wavelengths.

Fig 8

(A)-(B) In the transverse plane. (C)-(D) In the sagittal plane. All scale bars represent 20 mm.

Photoacoustic reconstructions at both wavelengths, in the coronal and transverse plane, are presented as MIPs in S3 Fig.

Case 4

Patient 4 (56 years old) came to the hospital because of a self-detected lump in the left breast. In the lower outer quadrant of the breast, a palpable abnormality of approximately 15 mm was noticed during physical examination. This presented as an unsharply delineated density of approximately 20 mm on the x-ray images (Fig 9A). US showed a suspicious looking hypo-echogenic lesion at the location of the palpable abnormality (Fig 9B). Two 14G biopsies were obtained from the BI-RADS 5 mass. The specimens taken from the breast were indicative of a grade 3 invasive carcinoma NST. In MR investigation (Fig 9C)), the lesion was identifiable with a few satellite lesions surrounding the main lesion. The total size of the region was 25 mm. The most dorsal lesion was 5 mm away from the pectoralis muscle. The distance to the skin was 8 mm. Histopathology after neoadjuvant chemotherapy and lumpectomy confirmed the diagnosis of an invasive carcinoma NST, but the material in this specimen was of grade 2.

Fig 9. Case 4: Diagnostic images of an invasive carcinoma in the left breast.

Fig 9

L and R indicate left and right, respectively. (A) Craniocaudal x-ray (CC-MMG). (B) Ultrasound (US) image. (C) MIP of the subtraction dynamic T1 MR acquisition, with adjusted window level and width values for enhanced contrast. All scale bars represent 20 mm.

Photoacoustic images were again processed as described in Section 2.3. Similar to case 1, processed photoacoustic coronal MIPs of slabs were obtained and studied, see Fig 10A and 10B. All slabs have a thickness of 15 mm and are located relatively close to the chest wall, where the tumor is situated. Fig 10C shows an MR MIP of a slab of tissue containing the tumor (L1). A vessel indicated by V1 is also visible in PA images of both wavelengths. Sprouting from the main vessel indicated by V1, we see multiple small vessels directed at the tumor (V2 in Fig 10C), resembling a comb. These small vessels seem to also be apparent in PA images, best visible in the image obtained with 755 nm illumination (Fig 10A).

Fig 10. Case 4: Local MIPs of slabs with a thickness of 15 mm, near the main lesion, close to the chest wall, in the coronal view.

Fig 10

Photoacoustic images at 755 nm (A) and 1064 nm (B), compared to a post-contrast dynamic T1 MR image (C). All scale bars represent 20 mm.

Photoacoustic reconstructions at both wavelengths, in the coronal and transverse plane, are presented as MIPs in S4 Fig.

Discussion

In this work, we investigated 3D photoacoustic breast images, acquired with our PAM 2 system, of women diagnosed with one or more malignant breast lesions. A subset of four subjects was selected and presented. Reconstructed images were processed to enhance visibility of vascularization and decrease background noise. Processed images were analyzed and compared to conventional clinical images–x-ray, ultrasound and contrast-enhanced MR. The tumor site was localized in our PA images, after which an analysis of this region was performed. Given the visibility of vascularization in contrast-enhanced MR images and in our PA images, comparison with MR images was preferred, when available. Per case, a tailored analysis was presented. Markers indicative of malignancy were searched for in the tumoral region.

Overall, the most relevant image pattern associated with malignancies observed in PAM 2 images was the presence of spotty signals within the tumoral region. This can be attributed to inhomogeneities within the tumor itself, or to the small vessels around it. As shown in Fig 6D and Fig 8A–8C, this pattern was observed in cases 2 and 3 in which the main lesions were relatively large in size (25 mm and 30 mm, respectively) and located close to the skin (inferior part of the breast against the thoracic wall and behind the nipple-areola complex, respectively). Hence, their localization in the PA image was relatively easy and the areas were sufficiently illuminated. This finding is comparable to what was shown by Toi et al., who identified the presence of spotty signals inside the tumor as a marker for breast cancer. It was also stated that it might be a means of discriminating between invasive breast cancer and ductal carcinoma in situ [7]. In Ref. [8], scattered hypoxic points were hypothesized to be attributable to intratumoral bleeding.

Entropy maps, which describe the local degree of disorder in the image, showed promising results only for case 3, where we observed a relatively high level of entropy at the tumor site (Fig 8B and 8D). This finding is supported by a previous study by Lin et al. [10], which showed that cancerous regions can be characterized in a PA image by regions with high entropy. The hypothesis behind this finding is that cancer-associated angiogenesis induces the formation of chaotic and irregular vascular networks, and one of the expected image features can be the presence of vessels showing abrupt changes in amplitude. However, in case of insufficient illumination not covering the entire breast, entropy maps lose consistency and may fail in detecting abnormal regions in dark (insufficiently illuminated) regions of the volume. This problem was experienced in three out of the four analyzed cases (data not shown). Fig 8D also partly shows this problem where in the inferior part of the breast a low level of entropy is seen. This lower entropy is attributable to insufficient light fluence at 1064 nm illumination when a comparison is made with the processed reconstructed MIP image (Fig 8C, right).

For cases 1 and 4, it was not possible to find image patterns within the tumoral region that can be linked to malignancy. For case 1, it was relatively hard to identify the coronal PA slab that contained the same tissue as the coronal MR slab with the (main) lesion. As mentioned, similarities in vessel structures and shapes were used for orientation, but differences in the shape of the pendant breast in air (MR) and water (PAM 2) complicated this process. For example, vessels present in one PA slab of 20 mm could be deformed and spread over multiple MR slabs of 20 mm, due to the longer pendant breast when hanging in air. Moreover, in Fig 4A and 4B, we see that the breast was not optimally illuminated, a problem with this system which was already known [11]. With 1064 nm illumination, less of the breast was imaged than with 755 nm. Apart from correlation and localization difficulties, it can be that the imaging depth was not sufficient to include the tumoral region. For case 4, the coronal PA MIP image (S4 Fig) contained many (superficial) blood vessels, making it difficult to find descriptors of the malignancy located close to the pectoralis muscle. Therefore, a coronal MR slab of tissue containing the lesion was compared to a PA slab of tissue at the same location. Although also in this case we do not see features relatable to the tumor itself, we hypothesize that we see small vessels, in a comb-like structure, associated with the lesion (marked as V2 in Fig 10A and 10B).

To summarize, we found unique malignancy-associated image features within the tumoral region in two out of four cases (case 2 and 3), and tumor-related vessels in two cases (case 3 and 4). But in the current research phase, we need a priori knowledge about the lesion and its location, and correlate PA image features (mostly vascular structures) with image features of conventional clinical images. For example, in a blind study, without the MR image of case 4, the structures indicated with arrowhead 2 in Fig 10A and 10B would not have been identified as suspicious and related to a malignant lesion. Other studies also evaluate their PA breast images in correlation with MR or US images, either in an overlay or by using a hybrid imaging system [7, 8]. It could be that this is only necessary in the current ‘learning phase’, where we are looking for and investigating the feasibility and predictive value of image descriptors indicative of malignancy, and in need of a reference. Or, perhaps the technique could one day have a supplementary role in the clinic, used in a hybrid setting with MR or US. But at least for the research phase, until we know exactly the PA appearance of breast tumors, it would be recommended to continue correlating PA images with MR images, or have a hybrid system (with US seems the most obvious right now). In this work, resemblance between PA and MR vessels structures was used to identify tumoral regions. This would be easier when deforming images of one of the modalities to obtain similar breast shapes, as was done in Ref. [7]. This was not possible with the data presented in this work, due to a lack of a sufficient number of landmarks identifiable in both modalities, especially in ‘dark’ regions of the image.

In addition to entropy, there are other image descriptors (textural features) that can be used to quantitatively characterize an image. We evaluated the use of other first-order statistical descriptors and advanced textural features such as the co-occurrence matrix and the grey level size zone matrix features. However, it was extremely difficult to identify a set of features able to identify the tumoral region with good accuracy. Furthermore, the absence of an accurate localization of the tumor in the photoacoustic image limits the ability to evaluate the predictive performance of such descriptors. And, similarly as was mentioned for entropy maps, such methods would need homogeneous illumination, to be able to accurately compare malignant regions to healthy tissue. A homogenous illumination not only requires an improved illumination scheme, but also a central position of the breast within the imaging tank, as was also shown in Ref. [12] by making use of cups supporting the breast.

Other groups presented methods for identifying tumors related to vessel density. Lin et al. calculated vessel density values in the tumoral region and found it to be almost always higher than the healthy surrounding tissue [9]. Toi et al. counted all trunks and branches of vessels and found higher numbers in the affected breast than in the contralateral breast [7]. With this information alone, one can obviously not yet localize and visualize the malignant lesion. Strategies like this are promising for discriminating malignant from healthy tissue, but were unfortunately not applicable to our data, due to the inhomogeneous illumination and variations of breast positioning within the imaging volume.

This brings us to an important recommendation for further research: improve the homogeneity of the illumination and ensure central and reproducible positioning of the breast within the imaging volume, to optimize both illumination and detection. For our specific imaging system, the advantages of centrally positioning the breast have already been shown in Ref [12], where the design and development of breast-supporting cups is described. Scans obtained with these supporting cups also profit from stabilization, improving image quality. Furthermore, it would be beneficial to let the illumination beams of the two wavelengths spatially overlap, to open possibilities for oxygen saturation assessment, to enhance the method’s sensitivity given the clinical relevance of hypoxia [16].

Another option to enhance sensitivity of the method might lie in the use of contrast agents. Perhaps the intrinsic contrast of tumor-related vasculature is not going to be enough in all cases, and an extrinsic form of contrast would be needed, similar to the contrast enhancement after gadolinium injection in MR imaging. Apart from enhancing the ‘regular’ PA contrast, exogenous contrast agents may allow imaging of cellular and molecular events [17]. Contrast agents may for example bind to molecular indicators of angiogenesis (active targeting), or particles may accumulate in the tumor due to its leaky and unorganized blood vessels (passive targeting), resulting in a contrast mechanism very similar to that of DCE-MR. A lot of research goes into this topic, for example into developing smart particles that are sensitive to the acidity of the tissue and are able to shift absorption peaks [18]. However, one of the strengths of photoacoustic imaging, especially in comparison with DCE-MR imaging, is the noninvasiveness when making use of the tissue’s intrinsic contrast. Therefore, the use of an exogenous contrast agent for breast imaging should only be considered when proven necessary.

In general, it seems that we have to look for additional features, apart from the morphology of blood vessels, to be able to discriminate malignant from healthy tissue when assessing images without a priori information. Options already mentioned are to do hybrid imaging with MR or US, and quantitative image interpretation methods like vessel density maps. Oxygen saturation assessment has been shown to be of added value, in small cohorts [7, 8]. With the PAM 2 system, we have seen image features that are indicative of breast malignancies in a few patients, but more research is needed to confirm these findings and hopefully deduce more features to enhance the method’s sensitivity. To develop a full diagnostic-feature set, studies will be performed on a larger dataset which will include benign cases for comparison. It is therefore recommended to continue research with an updated version of the current system, with an improved illumination system (in terms of illuminating more of the tissue surface, but also spatially overlapping of beams of different wavelengths). Moreover, a means to stabilize and position the breast, such as described in Ref [12], is recommended for further research. And ideally, an updated system would have a built-in extra modality for anatomical reference, where ultrasonography is an obvious choice.

Supporting information

S1 Table. Subject characteristics.

‘NST’ = non-specific type, ‘DD’ = differential diagnosis, ‘oc’ = o’clock. Subjects with IDs 1 through 4 are discussed in detail in this work. aDiagnosis of malignant lesions was based on histopathological examination of biopsy specimens. For cases studied in detail in this work, results of histology of lumpectomy or mastectomy were also obtained, but not included in this table.

(DOCX)

S1 Fig. Case 1: Comparison of photoacoustic with conventional MR images.

(A) Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths. (B) Post-contrast dynamic T1 MR MIPs in the same two planes. All scale bars represent 20 mm.

(TIF)

S2 Fig. Case 2: Comparison of photoacoustic with conventional MR images.

(A) Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths. (B) Post-contrast dynamic T1 MR MIPs in the same two planes. All scale bars represent 20 mm.

(TIF)

S3 Fig. Case 3: Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths.

All scale bars represent 20 mm.

(TIF)

S4 Fig. Case 4: Comparison of photoacoustic with conventional MR images.

(A) Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths. (B) Post-contrast dynamic T1 MR MIPs in the same two planes. All scale bars represent 20 mm.

(TIF)

S5 Fig. Case 1: Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths of the contralateral healthy breast.

All scale bars represent 20 mm.

(TIF)

S6 Fig. Case 3: Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths of the contralateral healthy breast.

All scale bars represent 20 mm.

(TIF)

Acknowledgments

Authors would like to thank patients for participating in this study and all involved medical staff for their collaboration. Rutger Pompe van Meerdervoort and Laurens Alink are thanked for technical help and assistance.

Data Availability

Data has been uploaded to the figshare repository: https://figshare.com/s/030561cd4ca6f1c83256.

Funding Statement

Stichting Achmea Gezondheidszorg, Project No. Z620., author W.S., https://www.zilverenkruis.nl/zorgaanbieders/visie-en-beleid/innovatie/sag Health~Holland LSI-TKH PPP project SACAMIR (No. LSHM17007), author S.M., https://www.health-holland.com/funding-opportunities/tki-match PAMMOTH project funded by the EU's Horizon 2020 RIA H2020 ICT 2016-2017 under Grant Agreement No. 732411, author S.M., https://ec.europa.eu/info/research-and-innovation/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-2020_en The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Manohar S, Dantuma M. Current and future trends in photoacoustic breast imaging. Photoacoustics. 2019;16:100134. doi: 10.1016/j.pacs.2019.04.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Attia ABE, Balasundaram G, Moothanchery M, Dinish US, Bi R, Ntziachristos V, et al. A review of clinical photoacoustic imaging: current and future trends. Photoacoustics. 2019;16:100144. doi: 10.1016/j.pacs.2019.100144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262 [DOI] [PubMed] [Google Scholar]
  • 4.Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi: 10.1016/j.cell.2011.02.013 [DOI] [PubMed] [Google Scholar]
  • 5.Heijblom M, Piras D, Brinkhuis M, Van Hespen JCG, Van Den Engh FM, Van Der Schaaf M, et al. Photoacoustic image patterns of breast carcinoma and comparisons with Magnetic Resonance Imaging and vascular stained histopathology. Scientific Reports. 2015;5:11778. doi: 10.1038/srep11778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Heijblom M, Piras D, van den Engh FM, van der Schaaf M, Klaase JM, Steenbergen W, et al. The state of the art in breast imaging using the Twente Photoacoustic Mammoscope: results from 31 measurements on malignancies. European Radiology. 2016;26(11):3874–87. doi: 10.1007/s00330-016-4240-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Toi M, Asao Y, Matsumoto Y, Sekiguchi H, Yoshikawa A, Takada M, et al. Visualization of tumor-related blood vessels in human breast by photoacoustic imaging system with a hemispherical detector array. Scientific Reports. 2017;7:41970. doi: 10.1038/srep41970 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Matsumoto Y, Asao Y, Sekiguchi H, Yoshikawa A, Ishii T, Nagae K-i, et al. Visualising peripheral arterioles and venules through high-resolution and large-area photoacoustic imaging. Scientific Reports. 2018;8(1):14930. doi: 10.1038/s41598-018-33255-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Lin L, Hu P, Shi J, Appleton CM, Maslov K, Li L, et al. Single-breath-hold photoacoustic computed tomography of the breast. Nature Communications. 2018;9(1):2352. doi: 10.1038/s41467-018-04576-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lin L, Tong X, Hu P, Invernizzi M, Lai L, Wang LV. Photoacoustic computed tomography of breast cancer in response to neoadjuvant chemotherapy. Advanced Science. 2021;8(7):2003396. doi: 10.1002/advs.202003396 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Schoustra SM, Piras D, Huijink R, Op’t Root TJ, Alink L, Kobold WM, et al. Twente Photoacoustic Mammoscope 2: system overview and three-dimensional vascular network images in healthy breasts. Journal of biomedical optics. 2019;24(12):121909. doi: 10.1117/1.JBO.24.12.121909 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Schoustra SM, op ’t Root TJPM, Pompe van Meerdervoort RP, Alink L, Steenbergen W, Manohar S. Pendant breast immobilization and positioning in photoacoustic tomographic imaging. Photoacoustics. 2021;21:100238. doi: 10.1016/j.pacs.2020.100238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Marczak W. Water as a standard in the measurements of speed of sound in liquids. The Journal of the Acoustical Society of America. 1997;102(5):2776–9. doi: 10.1121/1.420332 [DOI] [Google Scholar]
  • 14.Frangi AF, Niessen WJ, Vincken KL, Viergever MA, editors. Multiscale vessel enhancement filtering. International conference on medical image computing and computer-assisted intervention; 1998: Springer.
  • 15.Lin L, Hu P, Tong X, Na S, Cao R, Yuan X, et al. High-speed three-dimensional photoacoustic computed tomography for preclinical research and clinical translation. Nature Communications. 2021;12(1):882. doi: 10.1038/s41467-021-21232-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute. 2001;93(4):266–76. doi: 10.1093/jnci/93.4.266 [DOI] [PubMed] [Google Scholar]
  • 17.Luke GP, Yeager D, Emelianov SY. Biomedical applications of photoacoustic imaging with exogenous contrast agents. Annals of Biomedical Engineering. 2012;40(2):422–37. doi: 10.1007/s10439-011-0449-4 [DOI] [PubMed] [Google Scholar]
  • 18.Song J, Kim J, Hwang S, Jeon M, Jeong S, Kim C, et al. “Smart” gold nanoparticles for photoacoustic imaging: an imaging contrast agent responsive to the cancer microenvironment and signal amplification via pH-induced aggregation. Chemical Communications. 2016;52(53):8287–90. doi: 10.1039/c6cc03100e [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Jeeun Kang

6 Sep 2022

PONE-D-22-20783Imaging breast malignancies with the Twente Photoacoustic Mammoscope 2PLOS ONE

Dear Dr. Schoustra,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 21 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jeeun Kang, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in your Competing Interests section:  

"I have read the journal's policy and the authors of this manuscript have the following competing interests: author Klazen has a financial interest in PA Imaging Holding B.V., via PAMARA Holding B.V."

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now 

 This information should be included in your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Competing Interests section: 

"I have read the journal's policy and the authors of this manuscript have the following competing interests: author Klazen has a financial interest in PA Imaging Holding B.V., via PAMARA Holding B.V."

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. 

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors reported clinical measurements of breast cancer patients with the 3D Twente photoacoustic mammoscope prototype. Specifically, 30 patients in total were scanned and 4 out of 19 malignant cases were closely investigated. Photoacoustic imaging results were qualitatively compared with craniocaudal X-ray images, ultrasound images, and MRI images. Even though a larger cohort is expected for more convincing conclusions, the scientific findings of the four cases are of interest to this journal. The following aspects can be improved before further consideration of publication:

1. One caveat of the study is that there is no control group. It is unclear how different images will look like in benign cases, especially in PA images. Authors should at least analyze some benign cases and show the X-ray, MRI, US, and PA images for comparison.

2. The authors claim that “to enhance signals coming from the deeper vessels, adaptive intensity modulation was applied”. However, from the justification as well as results shown in figures (such as Fig 6), it seems that adaptive intensity modulation does not compensate for low illumination in deep regions. Instead, it adjusts image intensity with respect to local variability, which is more anatomy dependent rather than depth dependent. Please elaborate or correct.

3. To compensate for depth dependent PA intensity, optical fluence compensation is necessary, which is missing in this work. There have been multiple works on optical fluence compensation for breast. Suggest authors at least implementing a simple model-based method to consider exponentially attenuated light fluence given the boundary of the breast.

4. Also in image processing, why are the final images obtained by summing the adaptive modulated image and the median filtered image, instead of applying the adaptive modulation directly on the filtered image?

5. It is difficult to correlate different modalities without registration. The authors discussed the difficulty of cross-modality registration due to a lack of anatomical landmarks, but also mentioned a previous work where MRI and PA images are deformably registered and fused in reference [7] in Introduction. Why not applying the same technique to register at least MR and PA images?

Other comments:

6. In Materials and Methods, the authors mentioned that two US probes were used in the study, i.e. an L12-5 50 and an L18-5. However, only one ultrasound image was shown for each case in Results. Please elaborate the difference of the images acquired from the two probes, and how they were used in diagnosis.

7. How does the entropy map look like for the other three cases?

8. In discussion, the authors explained that the oxygen saturation was not evaluated due to the difference in illuminated tissue with the two wavelengths. This is confusing, why would the illuminated tissue change at different wavelengths? Please clarify.

9. The discussion of improvements achieved from this work compared with the previous generation of Twente mammoscope [5, 6] is inadequate.

10. The discussion can be organized more systematically and concisely by concluding all cases by their features, instead of listing one by one again as in Results. Suggest authors using “can be” instead of “might be” or “seems that” to conject.

Reviewer #2: The manuscript verified the clinical feasibility of PAM-02 system to diagnose breast cancer. Overall the manuscript is acceptable to publication. Please address the minor question of the PAM-02 system.

- The authors used 795nm and 1064nm lasers for imaging. Please justify why both wavelength are chosen. and other research (10.1038/s41467-018-04576-z) stated single 1064 laser was used to detect breast cancer, why did you use dual-band laser?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Mar 2;18(3):e0281434. doi: 10.1371/journal.pone.0281434.r002

Author response to Decision Letter 0


8 Nov 2022

Dear editor and dear reviewers,

responses to your comments have been provided in the Response to Reviewers uploaded document.

Best regards,

Bruno De Santi

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Jeeun Kang

29 Nov 2022

PONE-D-22-20783R1Imaging breast malignancies with the Twente Photoacoustic Mammoscope 2PLOS ONE

Dear Dr. De Santi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that minor revision would make your article fully satisfy PLOS ONE’s publication criteria. Therefore, we invite you to submit a revised version of the manuscript that addresses the minor points raised during the review process.

Please submit your revised manuscript by Jan 13 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jeeun Kang, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Partially addressed:

Comment 1: Let alone the benign cases for now, is it possible to show images of normal breasts so that readers can have a clearer sense how the vascular features are different in breast tumors from normal breasts?

Suggestions:

Comments 2, 3, 4, 5, 7 are well addressed. If the authors choose to publish the peer review history then it might be fine. Otherwise, the revised manuscript is a bit too simplified. If the authors choose not to publish the peer review history, suggest authors include the analysis and justifications that you responded to the rebuttal to the Discussion Section to make the manuscript more comprehensive. Figures R2, R3, R5, R7 should be added to Supporting Information. Figure R4 should be added to Methods.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PONE-D-22-20783_YWu_R2.docx

PLoS One. 2023 Mar 2;18(3):e0281434. doi: 10.1371/journal.pone.0281434.r004

Author response to Decision Letter 1


13 Jan 2023

We thank both reviewers for the appreciation of the manuscript and the first response to the reviewers.

We accepted the suggestions by reviewer 1. The submission is modified as follows:

1) We added Supplementary Figures 5 and 6, which show the photoacoustic reconstructions of the healthy contralateral breast for cases 1 and 3. As mentioned in our first response, we believe that at this stage of the research with our instrument, a comparison between ipsilateral and contralateral breasts is not insightful. The reason is mainly the absence of immobilization of the breast, which can result in movements in one case but less in another case. This can result in unpredictable artifacts and blurring in one breast but not in the other, making comparison between images of the two breasts unproductive.

2) As suggested, we give permission to publish the first response to reviewers.

3) Finally, reviewer 1 also suggested including Figure R4 (in the response to reviewers document) in the Methods section of the manuscript. As this figure was sharing part of the content with Figure 2, we decided to combine the two figures in order to clearly show the pipeline steps and each intermediate result.

Best regards,

Bruno De Santi

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 2

Jeeun Kang

24 Jan 2023

Imaging breast malignancies with the Twente Photoacoustic Mammoscope 2

PONE-D-22-20783R2

Dear Dr. De Santi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jeeun Kang, Ph.D.

Academic Editor

PLOS ONE

Acceptance letter

Jeeun Kang

20 Feb 2023

PONE-D-22-20783R2

Imaging breast malignancies with the Twente Photoacoustic Mammoscope 2

Dear Dr. De Santi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jeeun Kang

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Subject characteristics.

    ‘NST’ = non-specific type, ‘DD’ = differential diagnosis, ‘oc’ = o’clock. Subjects with IDs 1 through 4 are discussed in detail in this work. aDiagnosis of malignant lesions was based on histopathological examination of biopsy specimens. For cases studied in detail in this work, results of histology of lumpectomy or mastectomy were also obtained, but not included in this table.

    (DOCX)

    S1 Fig. Case 1: Comparison of photoacoustic with conventional MR images.

    (A) Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths. (B) Post-contrast dynamic T1 MR MIPs in the same two planes. All scale bars represent 20 mm.

    (TIF)

    S2 Fig. Case 2: Comparison of photoacoustic with conventional MR images.

    (A) Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths. (B) Post-contrast dynamic T1 MR MIPs in the same two planes. All scale bars represent 20 mm.

    (TIF)

    S3 Fig. Case 3: Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths.

    All scale bars represent 20 mm.

    (TIF)

    S4 Fig. Case 4: Comparison of photoacoustic with conventional MR images.

    (A) Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths. (B) Post-contrast dynamic T1 MR MIPs in the same two planes. All scale bars represent 20 mm.

    (TIF)

    S5 Fig. Case 1: Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths of the contralateral healthy breast.

    All scale bars represent 20 mm.

    (TIF)

    S6 Fig. Case 3: Photoacoustic maximum intensity projections (MIPs) in two planes (coronal (top) and transverse (bottom)), at two illumination wavelengths of the contralateral healthy breast.

    All scale bars represent 20 mm.

    (TIF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: PONE-D-22-20783_YWu_R2.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    Data has been uploaded to the figshare repository: https://figshare.com/s/030561cd4ca6f1c83256.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES